Cost-Effectiveness of Once-Weekly Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in the UK

被引：0
|
作者：
Muszbek, N. [1 ]
Angdembe, A. [1 ]
Garcia-Vidal, C. [2 ]
Bielicka, I [3 ]
Abrams, K. [1 ]
Tolley, K. [4 ]
Ruhnke, M. [5 ]
Lebmeier, M.
Hawkins, N. [1 ]
Manamley, N. [3 ]
Dickerson, S. [3 ]
机构：
[1] Visible Analyt, Oxford, Oxon, England
[2] Hosp Clin Barcelona, Barcelona, Catalonia, Spain
[3] Mundipharma Res Ltd, Cambridge, Cambs, England
[4] Tolley Hlth Econ, Buxton, DBY, England
[5] Helios Klinikum Aue, Aue Bad Schlema, Sachsen, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE332
引用
下载
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF EXENATIDE ONCE-WEEKLY VERSUS DULAGLUTIDE, LIRAGLUTIDE AND LIXISENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM THE UK NHS PERSPECTIVE
    Charokopou, M.
    Chuang, L.
    Verheggen, B.
    Gibson, D.
    Grandy, S.
    Kartman, B.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A606
  • [32] Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective
    Chuang, L. H.
    Verheggen, B. G.
    Charokopou, M.
    Gibson, D.
    Grandy, S.
    Kartman, B.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1127 - 1134
  • [33] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Ataru Igarashi
    Barnaby Hunt
    Lars Wilkinson
    Jakob Langer
    Richard F. Pollock
    Advances in Therapy, 2020, 37 : 4446 - 4457
  • [34] Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11
    Evans, Marc
    Chubb, Barrie
    Malkin, Samuel J. P.
    Berry, Sasha
    Lawson, Jack
    Hunt, Barnaby
    DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 491 - 500
  • [35] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Igarashi, Ataru
    Hunt, Barnaby
    Wilkinson, Lars
    Langer, Jakob
    Pollock, Richard F.
    ADVANCES IN THERAPY, 2020, 37 (10) : 4446 - 4457
  • [36] Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis
    Neoh, Chin Fen
    Liew, Danny
    Slavin, Monica
    Marriott, Debbie
    Chen, Sharon C. -A.
    Morrissey, Orla
    Stewart, Kay
    Kong, David C. M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (08) : 1906 - 1915
  • [37] A cost-effectiveness analysis model for treatment of candidiasis and invasive aspergillosis in Mexico
    Quevedo, JFM
    Contreras, I
    Garcia-Contreras, F
    Nevarez, A
    Constantino-Casas, P
    Garduño, J
    VALUE IN HEALTH, 2005, 8 (03) : 308 - 308
  • [38] Appropriateness and cost-effectiveness in the treatment of invasive candidiasis in Internal Medicine Wards
    Tagliaferri, Enrico
    Menichetti, Francesco
    ITALIAN JOURNAL OF MEDICINE, 2014, 8 (04) : 221 - 224
  • [39] Once-weekly treatment for osteoporosis
    Stone, M
    HOSPITAL MEDICINE, 2002, 63 (04): : 230 - 232
  • [40] Rezafungin: a novel antifungal for the treatment of invasive candidiasis
    Ham, Young Yoon
    Lewis, James S., II
    Thompson, George R., III
    FUTURE MICROBIOLOGY, 2021, 16 (01) : 27 - 36
12345